Even though the IDH mutation is predominantly observed in glioma patients with low-grade tumors, one of the advantages of using a high-grade tumor model in preclinical studies is to reach a high enough rate of tumor growth potential in these models to accentuate any potential differences in uptake of the PET radiotracers investigated. The gene discussed is IDH1; the disease is neoplasm.